Repeat PET-CT Scans: — What Each Follow-Up Costs

The cost of a PET-CT is driven almost entirely by what happens on the day: a fresh radiotracer dose prepared that morning for you specifically, time on the scanner, and a radiologist's written report. The radiotracer — fluorodeoxyglucose — decays so rapidly that it cannot be made in advance or shared between patients. That preparation cost is the same each time, regardless of how many scans you have had. There is no repeat-patient discount built into PET-CT pricing the way there might be for something manufactured in bulk and stored.

That depends on your cancer type, your stage, and the outcome of your treatment. For most lymphomas and head and neck cancers, an end-of-treatment PET-CT is almost always recommended to confirm whether the treatment worked. After that, NCCN and ASCO guidance for many cancers moves to CT scanning or clinical follow-up rather than routine PET-CT — a PET is ordered when a specific clinical question needs answering, not on a fixed calendar. Your oncologist can give you the planned schedule for your specific protocol. Asking for it in writing at your next appointment is reasonable and gives you something concrete to budget around.

Most cashless health insurance policies do cover surveillance PET-CT for cancer patients, but cover is not automatic for each scan. You usually need a letter from your oncologist stating the clinical reason before each one. Some policies have an annual cap on diagnostic imaging costs, and some require pre-authorisation for every scan rather than a one-time approval for the whole surveillance period. Read your policy documents or call your insurer before the next scan date — not on the day of the scan — to understand exactly what is required and whether your plan has any imaging limits.

For many cancers, guidelines from NCCN and ASCO do recommend CT rather than PET-CT for routine surveillance, because CT is less expensive and involves lower radiation exposure per scan. PET-CT is specifically recommended when the question is whether treatment has worked at the end of therapy, or when a finding needs its metabolic activity assessed to clarify what it is. If your oncologist has ordered a PET-CT for a follow-up scan, ask what it will show that a CT would not — that is a reasonable question, and your oncologist should be able to answer it directly.

Tell your oncology team before the scan date — not after — if cost is a barrier. A surveillance scan is scheduled at a particular point because that is when the information it provides is most clinically useful. Delaying it without your team's knowledge can mean a recurrence goes undetected for longer than your protocol was designed to allow. When you tell your team in advance, they can explore options with you: whether the scan date has any clinical flexibility, whether a scheme or patient assistance programme applies, or whether a payment arrangement is possible. There is almost always a path forward; it starts with an honest conversation.

There is no single figure, because the number of scans in a year varies by cancer type and by where you are in your treatment journey. The year immediately after treatment ends tends to be the most scan-intensive. From year two onward, many protocols move to fewer PET-CTs or switch to CT for routine surveillance. The most accurate way to estimate your annual cost is to ask your oncologist for the planned scan schedule and multiply the number of PET-CTs by the indicative price at the imaging centre being used. That calculation, done once, gives you a real number to plan around rather than an approximation.